Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Repligen (RGN) Stock Price & Analysis

RGN Stock Chart & Stats

€155.70-€14.50(-8.52%)
At close: 5:30 PM GMT+1
EUR 130EUR 140EUR 1503 Aug5 Aug9 Oct30 Oct
Day’s Range
EUR 155.70 - EUR 169.50
52-Week Range
EUR 86.32 - EUR 170.65
Previous Close
EUR 170.20
Volume
0
Average Volume (3M)
1
Market Cap
EUR 10.03B
Enterprise Value
EUR 10.70B
Total Cash (Recent Filing)
EUR 862.98M
Total Debt (Recent Filing)
EUR 692.24M
Price to Earnings (P/E)
―
Beta
0.97
Next Earnings
Feb 24, 2027 (Est.)
EPS Estimate
0.47
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Recurring Consumables Model

Validated consumables and replaceable process components can create repeat purchasing and customer stickiness. Revalidation requirements make switching less attractive, supporting recurring revenue, durable account relationships, and more predictable demand as biologics manufacturing expands.

Cash Generation And Balance Sheet

Strong operating and free cash flow provide internal funding for investment, acquisitions, and debt service. Combined with moderate leverage and substantial equity, this gives Repligen financial flexibility to pursue growth while absorbing normal business volatility.

Diversified Growth Platform

Growth across bioprocessing franchises and the completed BioLife acquisition broadens Repligen’s exposure to cell therapy and other expanding modalities. The combination of organic growth and complementary capabilities supports a larger, more diversified long-term revenue base.

Bears Say

Weak Net Profitability

Negative net income reduces earnings quality and makes reported profitability less reliable despite positive operating cash flow and EBITDA. Margins below prior peaks indicate that the company has not yet fully restored its former earnings power or operating efficiency.

Filtration And Equipment Headwinds

Filtration weakness directly pressures an established product franchise, while delayed equipment conversion pushes recognized revenue into later periods. These issues can make near-term growth uneven and increase reliance on stronger chromatography, protein, and analytics performance.

Convertible Financing And Dilution

The refinancing extends maturities and raises cash, but the large convertible issuance adds future dilution risk if conversion occurs. It also increases the complexity of capital allocation and may constrain per-share benefits from otherwise successful operating growth.

Repligen News

RGN FAQ

What was Repligen’s price range in the past 12 months?
Repligen lowest stock price was €86.32 and its highest was €170.65 in the past 12 months.
What is Repligen’s market cap?
Repligen’s market cap is €10.03B.
When is Repligen’s upcoming earnings report date?
Repligen’s next earnings report is estimated for Feb 24, 2027 (not yet confirmed), which is in 115 days.
How were Repligen’s earnings last quarter?
Repligen released its earnings results on Oct 27, 2026. The company reported €0.473 earnings per share for the quarter, beating the consensus estimate of €0.413 by €0.06.
Is Repligen overvalued?
According to Wall Street analysts Repligen’s price is currently Undervalued.
Does Repligen pay dividends?
Repligen does not currently pay dividends.
What is Repligen’s EPS estimate?
Repligen’s EPS estimate is 0.47.
How many shares outstanding does Repligen have?
Repligen has 63,490,364 shares outstanding.
What happened to Repligen’s price movement after its last earnings report?
Repligen reported an EPS of €0.473 in its last earnings report, beating expectations of €0.413. Following the earnings report the stock price went down -2.655%.
Which hedge fund is a major shareholder of Repligen?
Hedge funds hold Repligen shares: the largest hedge-fund position in Repligen is 1,898,504,359 shares, and hedge funds increased their holdings by 713.3K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology